Evogene (TSE:EVGN – Free Report) had its price objective cut by Echelon Wealth Partners from C$6.25 to C$6.00 in a report released on Friday morning, BayStreet.CA reports. They currently have a buy rating on the stock. Separately, Desjardins cut their target price on shares of Evogene from C$4.50 to C$4.25 and set a buy rating […]